GI Permeability Change in Response to Aquamin®

Phase 2 Completed NCT04855799

Summary

This trial is being completed to learn about how Aquamin® affects gastrointestinal permeability, or the control of material passing from inside the gastrointestinal tract through the gut wall into the rest of the body, in people with ulcerative colitis (UC), Irritable Bowel Syndrome with diarrhea (IBS-D), and in healthy individuals.

Change in the Lactulose:Mannitol Ratio in Urine by Comparing Values at 90-days (Post-intervention) to Baseline (Pre-intervention) Levels.

Baseline (pre-intervention), 90 days (post-intervention)

Mannitol Levels in Urine Samples

90 days · mgs

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Coliti — Janssen Research & Development, LLC
• A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Seve — Hoffmann-La Roche
• A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerativ — Janssen Research & Development, LLC
• A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Mode — Janssen Research & Development, LLC
• Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Tre — First Affiliated Hospital of Kunming Medical University
• ENhanced Recovery in CHildren Undergoing Surgery — Northwestern University

All trials